- 12C2 (See other available formats)
- Other Names
- Mouse IgG2a, κ
- Ave. Rating
- Submit a Review
- Product Citations
|Cat #||Size||Price||Quantity Avail.||Save|
CD304, also known as neuropilin-1, BDCA-4 and VEGF165R, is a 140 kD type I transmembrane protein. Its extracellular region contains 2 CUB, 2 FV/FVIII, and one MAM domain; a soluble isoform is produced by alternative mRNA splicing. CD304 is involved in angiogenesis, neural development, and tumor metastasis. It's expressed by plasmacytoid dendritic cells, thymocytes, neurons, endothelium, and a subset of TFH cells. CD304 is also expressed in several carcinomas, and a high expression of this molecule in prostate cancer correlates with a poor prognosis.Product Details
- Antibody Type
- Host Species
- CD304-Fc Fusion protein
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
- The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 711™ under optimal conditions.
- Lot-specific (please contact technical support for concentration and total µg amount, or use our Lookup tool if you have a lot number.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Brilliant Violet 711™ excites at 405 nm and emits at 711 nm. The bandpass filter 710/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 711™ is a trademark of Sirigen Group Ltd.
Learn more about Brilliant Violet™.
This product is subject to proprietary rights of Becton, Dickinson and Company and its affiliates. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. patent(s), pending patent applications and/or foreign equivalents.
- Excitation Laser
Violet Laser (405 nm)
AB_2876674 (BioLegend Cat. No. 354533)
AB_2876674 (BioLegend Cat. No. 354534)
- Type I transmembrane protein, 140 kD, 2 complement binding domains (CUB), 2 coagulation factor V/VIII homology domains (FV/FVIII), one meprin, A5, receptor tyrosine phosphatase domain (MAM)
Plasmacytoid dendritic cells, thymocytes, subset of follicular helper T cells (TFH), endothelial cells, neurons, some carcinomas
- Angiogenesis, neuronal development, tumor metastasis
- VEGF165, semaphorin-3A
- Cell Type
- Dendritic cells, Endothelial cells, Neurons, Tfh, Thymocytes
- Biology Area
- Angiogenesis, Cell Adhesion, Cell Biology, Immunology, Innate Immunity, Neuroscience, Synaptic Biology
- Molecular Family
- Adhesion Molecules, CD Molecules
- Antigen References
1. Mizui M and Kikutani H. 2008. Immunity 28:302.
2. Hamerlik P, et al. 2012. J. Exp. Med. 209:507.
3. Karjalainen K, et al. 2011. Blood 117:920.
4. Lepelletier Y, et al. 2007. P. Natl. Acad. Sci. USA 104:5545.
- Gene ID
- 8829 View all products for this Gene ID
- View information about CD304 on UniProt.org
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.